New GLP-1 Drugs Pipeline: 2026–2027 Guide
✓ Free to download
Explore the pipeline of new GLP-1 drugs expected in 2026–2027, including those in late-stage development for weight management.
The GLP-1 drug landscape is changing faster in 2026 than in any previous year. Three new options have been approved in the US since December 2025, one more is under FDA review, and others with extraordinary trial data are moving through Phase 3.
This guide covers what is approved or approaching approval, with real trial numbers, not just headlines. Status is as of October 2026 and can change quickly. Approvals listed here are US (FDA) unless stated; availability in the UK and India differs.
ALREADY APPROVED IN 2025–2026
Wegovy Pill (oral semaglutide 25 mg)
FDA approved: December 22, 2025
The first oral GLP-1 medication approved specifically for weight loss. Daily tablet, same molecule as Wegovy injection.
- Weight loss: 16.6% average at 64 weeks in people who stayed on treatment (13.6% counting everyone), versus 2.7% (2.2%) on placebo (OASIS 4 trial)
- Restriction: Must be taken on an empty stomach with max 120 ml water; 30-minute wait before eating
- Also approved for: Cardiovascular risk reduction in obesity + CVD
- Available now: Yes, in the US
Wegovy HD (semaglutide 7.2 mg)
FDA approved: March 19, 2026
The highest-dose Wegovy injection, for patients who need more from their GLP-1 therapy.
- Weight loss: 20.7% average at 72 weeks in people who stayed on treatment (18.7% counting everyone) in STEP UP; about one in three lost 25% or more
- Format: Weekly injection, same as standard Wegovy
- Who it is for: Adults who have tolerated Wegovy 2.4 mg for at least 4 weeks and for whom their prescriber decides more weight reduction is needed
- Available now: US launch was planned for April 2026; check with your pharmacy
Zepbound for Sleep Apnea (tirzepatide)
FDA approved: December 20, 2024
First drug ever approved for obstructive sleep apnea. Tirzepatide reduces breathing disruptions per hour by approximately 62% alongside substantial weight loss.
- Indication: Moderate-to-severe OSA in adults with obesity
- Available now: Yes
Wegovy for Fatty Liver (MASH)
FDA approved (accelerated): August 15, 2025
First GLP-1 to receive approval for liver disease. Based on ESSENCE trial data showing MASH resolution and fibrosis improvement.
- Indication: Noncirrhotic MASH with F2–F3 fibrosis in adults
- Available now: Yes (using existing Wegovy 2.4 mg injection)
Foundayo (orforglipron, Eli Lilly)
FDA approved: April 1, 2026
A once-daily pill with no food or water restrictions, the first of its kind.
- Mechanism: Non-peptide small molecule GLP-1 receptor agonist
- Weight loss: Average 27.3 lbs (12.4%) at 72 weeks on the highest dose in ATTAIN-1, in people who stayed on treatment, versus 0.9% on placebo (obesity, no T2D)
- Key advantage: No injection, no fasting, no water restrictions, take any time
- Head-to-head: In ACHIEVE-3 (adults with type 2 diabetes, 52 weeks), weight loss was 9.2% on orforglipron 36 mg versus 5.3% on oral semaglutide 14 mg
- Available now: Yes, in the US
IN FDA REVIEW
CagriSema (Novo Nordisk)
NDA submitted: December 18, 2025 | FDA review: 2026
A first-in-class combination of semaglutide (GLP-1) + cagrilintide (amylin analogue) in a single weekly injection.
- Mechanism: Amylin + GLP-1 dual action, two different appetite suppression pathways
- Weight loss: 22.7% at 68 weeks in REDEFINE 1 in people who stayed on treatment (20.4% counting everyone) vs 2.3% placebo
- vs Semaglutide alone: 22.7% vs 16.1%, a meaningful improvement
- vs Tirzepatide: In REDEFINE 4 (84 weeks), CagriSema gave 23.0% weight loss versus 25.5% with Zepbound 15 mg and did not show non-inferiority
- Status (October 2026): Still under FDA review; not yet approved
PHASE 3
Retatrutide (Eli Lilly)
Phase 3 (multiple trials) | Approval not expected before 2027 at the earliest
The drug with the most extraordinary trial numbers in GLP-1 history.
- Mechanism: Triple agonist, GIP + GLP-1 + Glucagon receptors
- Weight loss: Up to 28.7% (71.2 lbs, 32.3 kg) at 68 weeks in TRIUMPH-4 (adults with obesity or overweight and knee osteoarthritis, without diabetes)
- TRIUMPH-1 (May 2026): Up to 25.0% average weight loss at 80 weeks on 12 mg, versus 3.9% on placebo, in 2,339 adults
- Phase 2: Up to 24.2% weight loss at 48 weeks
- Additional benefit: TRIUMPH-4 showed up to a 75.8% reduction in knee osteoarthritis pain scores (versus 40.3% on placebo)
- Note: Not approved; not available outside clinical trials
OTHER CANDIDATES TO WATCH
Survodutide (Boehringer Ingelheim + Zealand Pharma)
- Mechanism: GLP-1 + Glucagon dual agonist
- Phase 3 SYNCHRONIZE trials in obesity, plus Phase 3 trials in MASH (fatty liver)
- SYNCHRONIZE-1 (April 2026): up to 16.6% average weight loss at 76 weeks in people who stayed on treatment, versus 3.2% on placebo
- Phase 2: ~19% weight loss
- Strong liver disease data may give it a differentiated position
AMG 133 / Maridebart Cafraglutide (Amgen)
- Mechanism: GLP-1 agonist + GIPR antagonist (novel, blocks GIP rather than activating it)
- Monthly (or less frequent) injection, would be the first once-monthly GLP-1 option
- Phase 2: ~20% weight loss in 52 weeks
- Now in Phase 3 (MARITIME programme); no Phase 3 results reported as of August 2026
Pemvidutide (Altimmune)
- Mechanism: GLP-1 + Glucagon dual agonist
- Key angle: being studied for weight loss with relatively more fat loss and less lean mass loss
- Phase 2 (MOMENTUM): ~15.6% weight loss at 48 weeks
- The developer's Phase 3 programme is in MASH (fatty liver), not obesity
DISCONTINUED
Danuglipron (Pfizer) - ❌ DISCONTINUED April 2025
Pfizer pulled its oral GLP-1 candidate after a patient experienced potential drug-induced liver injury in a dose-optimisation study. The program has been terminated.
How to compare the options
| Drug | Type | Frequency | Avg. weight loss | Status |
|---|---|---|---|---|
| Wegovy pill | Oral (fasting req.) | Daily | ~16.6% | ✅ Approved Dec 2025 |
| Wegovy HD | Injection | Weekly | ~21% | ✅ Approved Mar 2026 |
| Foundayo (orforglipron) | Oral (no restrictions) | Daily | ~12.4% | ✅ Approved Apr 2026 |
| CagriSema | Injection | Weekly | ~20–23% | 🔄 FDA review |
| Retatrutide | Injection | Weekly | ~25–29% | Phase 3 |
| AMG 133 (MariTide) | Injection | Monthly | ~20% (Phase 2) | Phase 3 |
Trial figures come from different populations and trial lengths, so they cannot be compared directly.
What this means for current GLP-1 users
The landscape is expanding rapidly:
- There are now two oral GLP-1 options for weight loss in the US, with more likely to follow
- Some pipeline injectables may offer stronger weight loss than today's options, if approved
- A monthly injection may eventually reduce the logistical burden of weekly dosing
If you are currently on Ozempic, Wegovy, Mounjaro, or Zepbound and satisfied with your results, there is no reason to wait. If you have plateaued, talk to your prescriber about your options; do not stop or switch your medicine on your own, and avoid investigational drugs sold online outside clinical trials.
Weight Easy will support all newly approved GLP-1 drugs as they become available, so your dose tracking, symptom logs, and weight trends carry seamlessly across medication changes.
Related Articles
- CagriSema: Novo Nordisk's 22.7% Weight Loss Drug Explained
- Retatrutide: The Triple Agonist Explained
- Orforglipron: The First Oral GLP-1 Pill
Final takeaway
2026 is the most active year in GLP-1 drug development. Three new options have been approved in the US (Wegovy pill, Wegovy HD, Foundayo), CagriSema is in FDA review, and retatrutide has produced some of the largest average weight losses reported in obesity trials. The options available to patients will look very different by the end of 2027.
Consult your healthcare provider about which option is most appropriate for your situation.
Consult your healthcare provider before starting any medication.
Sources
- Wegovy FDA prescribing information: accessdata.fda.gov
- Wegovy pill approval and OASIS 4 results (Applied Clinical Trials, Dec 2025): appliedclinicaltrialsonline.com
- Wegovy HD approval, Novo Nordisk release (Mar 2026): placera.se
- Foundayo (orforglipron) approval, Lilly release (Apr 2026): biospace.com
- CagriSema FDA submission and REDEFINE 1, Novo Nordisk release (Dec 2025): biospace.com
- REDEFINE 4 results (Clinical Trials Arena, Feb 2026): clinicaltrialsarena.com
- Retatrutide TRIUMPH-4 results (Patient Care, Dec 2025): patientcareonline.com
- Retatrutide TRIUMPH-1 results (The Pharmaceutical Journal, May 2026): pharmaceutical-journal.com
- Survodutide SYNCHRONIZE-1 results (PharmaTimes, Apr 2026): pharmatimes.com
- MariTide Phase 3 programme, Amgen Q2 2026 results: amgen.com
- Pemvidutide Phase 3 MASH plans, Altimmune SEC filing (Apr 2026): sec.gov
FAQ
What new GLP-1 drugs are coming in 2026?
As of October 2026, three new options have been approved in the US: the Wegovy pill (December 2025), Wegovy HD 7.2 mg (March 2026) and orforglipron, sold as Foundayo (April 2026). CagriSema (Novo Nordisk's amylin + semaglutide combination) is still under FDA review.
What is the most powerful new GLP-1 drug?
Retatrutide (Eli Lilly's triple agonist) has produced some of the largest average weight losses reported in obesity drug trials: up to 28.7% (71.2 lbs, 32.3 kg) at 68 weeks in TRIUMPH-4, in adults with obesity or overweight and knee osteoarthritis. It is not approved yet, and approval is not expected before 2027 at the earliest.
Will there ever be a GLP-1 drug with no injection and no food restrictions?
Yes - orforglipron (Foundayo) was approved by the FDA on April 1, 2026 for chronic weight management. It is a non-peptide small molecule taken once daily as a pill, at any time of day, with no food or water restrictions. It is the first approved GLP-1 with this profile.
Is oral semaglutide (Wegovy pill) the same as orforglipron?
No. Both are daily oral GLP-1 medications, but they are different molecules. Wegovy pill (oral semaglutide 25 mg) requires fasting and water-only intake for 30 minutes after taking it. Orforglipron is a small molecule with no food restrictions. They were also compared head-to-head in people with type 2 diabetes (ACHIEVE-3): orforglipron 36 mg lowered blood sugar and weight more than oral semaglutide 14 mg.
Written by
Dietician / Nutritionist
Health Content Writer
Fashtana Khan is a Dietician / Nutritionist professional who contributes evidence-informed health and wellness content for Weight Easy.
View profile →Reviewed by
Dietician / Nutritionist
Senior Medical Reviewer
Dt Neha is a Dietician / Nutritionist professional who reviews Weight Easy health content for medical and editorial accuracy.
View profile →